The following is a list of trial data presentations from this year’s American Society of Hematology (ASH) annual meeting, which took place between December 10 and 13, 2005 in Atlanta. This list is not comprehensive; it includes only the events that we at BioMedTracker consider to be particularly relevant (e.g. failures, successes, new indications, potential blockbusters) and those catalysts that we had previously singled out for close attention in our 2005 ASH Catalyst Preview.

The trial data is broken down by indication. Please note that the abstracts summarizing the trial data presented at ASH are currently (as of December 15, 2005) available for review at the ASH website.

Acute Lymphocytic Leukemia (ALL)

Fodosine (BioCryst) – Abstract #881 12/10/05
New Phase II Data

Acute Myelogenous Leukemia (AML)

Dacogen (SuperGen) - Abstract #1852 12/11/2005
Dacogen as an Active First-line Treatment of Elderly

Anaplastic Large Cell Lymphoma (ALCL)

SGN-30 (Seattle Genetics) Abstract #3356 12/12/2005
Updated Data from Phase II Refractory ALCL Trial

Chronic Lymphocytic Leukemia (CLL)

Genasense (Genta) Abstract #2129 12/11/2005
New Phase I/II Data for Trial in combination with Rituxan and Fludarabine HuMax-CD20 (Medarex) Abstract #448 12/12/2005
New Phase I/II Data

Revlimid (Celgene) Abstract #447 12/12/2005
Updated Phase II Trial Data

Talabostat (Point Therapeutics) Abstract #2125 12/12/2005
Updated Phase II Trial Data

Chronic Myelogenous Leukemia (CML)

AG-858 (Antigenics) Abstract #1094 12/10/2005
Phase II Data for Gleevec Refractory Trial

Dasatinib (Bristol-Myers Squibb) Abstract #41 12/11/2005
Data from Phase II START-C CA180013 Study

Dasatinib (Bristol-Myers Squibb) Abstract #42 12/11/2005
Data from Phase II START-L CA180015 Study

Cutaneous T-Cell Lymphoma (CTCL)

Ad-IFNgamma (Transgene) Abstract #1497 12/10/2005
Updated Data from Phase I/II Trial

Revlimid (Celgene) Abstract #3351 12/12/2005
Phase II Data

Immune Thrombocytopenic Purpura (ITP)

AMG 531 (Amgen) Abstract #220 12/12/2005
Phase III Data from Extension Study

Multiple Myeloma

Avastin (Genentech) Abstract #2571 12/11/2005
Phase II Data

Revlimid (Celgene) Abstract #1565 12/10/2005
Data from MM-014 Trial

Thalomid (Celgene) Abstract #424 12/12/2005
Data from the Phase-III HOVON50/GMMG-HD3 Trial

Trisenox (Cephalon) Abstract #2564 12/11/2005
Phase II Data

Velcade (Millenium) Abstracts #783, 784, and 786 12/13/2005
Data from Multiple Studies

Myelodysplastic Syndrome (MDS)

Telintra (Telik) Abstract #2520 12/11/2005
Update from Phase II Trial

Dacogen (SuperGen) - Abstract #2515 12/11/2005
Data from Phase II and Phase III trials

Myelofibrosis with Myeloid Metaplasia (MMM)

Revlimid (Celgene) Abstract #377 12/12/2005
Updated Phase II Trial Data

Non-Hodgkin's Lymphoma (NHL)

HGS-ETR1 (Human Genome Sciences) Abstract #489 12/12/2005
Phase II clinical trial

IMMU-106 (Immunomedics) Abstract #2428 12/11/2005
Phase II Data

LY317615 (Eli Lilly) Abstract #934 12/10/2005
Phase II Trial Data

ONTAK (Ligand) Abstract #3350 12/12/2005
Updated Phase II Trial Data in T-Cell NHL

ONTAK (Ligand) Abstract #3349 12/12/2005
New Phase II Trial Data in B-Cell NHL in combination with Rituxan

Rituxan (Biogen Idec) Abstract #353 12/12/2005
EORTC 20981 Trial Data

Treanda (Cephalon) Abstract #923 12/10/2005
Data from Phase II SDX-105-02 Trial

Treanda (Cephalon) Abstract #229 12/12/2005
Updated Data from Phase II SDX-105-01 Trial